Published finding — does the expert body still believe it?
The HGB-206 (lovo-cel) trial's stated primary conclusion — Lentiviral β-globin gene therapy reduces or eliminates VOC events in severe sickle cell disease. — replicates in independent cohorts.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1243
The CLIMB-121 (exa-cel, sickle cell) trial's stated primary conclusion — CRISPR-Cas9 BCL11A editing (exa-cel) eliminates vaso-occlusive crises in severe sickle cell disease over multi-year follow-up. — replicates in independent cohorts.
0.1658
Recent follow-up analyses of HGB-206 (lovo-cel) are confirming the original effect size in real-world data.
0.1711
The HOPE-B (Hemgenix / etranacogene) trial's stated primary conclusion — AAV5 FIX-Padua gene therapy produces sustained Factor IX activity, reducing bleeds in severe hemophilia B. — replicates in independent cohorts.
0.1810
Recent follow-up analyses of CLIMB-121 (exa-cel, sickle cell) are confirming the original effect size in real-world data.
0.1939
By 2028, exa-cel or a comparable ex vivo gene-edited therapy will have treated >500 SCD patients globally with a durable VOC-free rate >90% at 3 years.
0.1947
Recent follow-up analyses of HOPE-B (Hemgenix / etranacogene) are confirming the original effect size in real-world data.